Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.

Abstract

OBJECTIVE:

Acquired immunodeficiency syndrome-related non-Hodgkin lymphoma is treated similarly to non-acquired immunodeficiency syndrome lymphoma, but it is not clear whether highly intensive regimens are beneficial for acquired immunodeficiency syndrome-related Burkitt lymphoma. We conducted a multicenter retrospective survey to clarify the clinical outcomes of acquired immunodeficiency syndrome-related Burkitt lymphoma in the combined antiretroviral therapy era in Japan.

METHODS:

We retrospectively analyzed the outcome of 33 patients with acquired immunodeficiency syndrome-related Burkitt lymphoma, who were diagnosed at five regional hospitals for human immunodeficiency virus/acquired immunodeficiency syndrome in Japan between January 2002 and December 2010.

RESULTS:

The median follow-up period was 20.0 months (range 0.5-92.7 months). Six (18.2%) patients were treated with cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate, ifosphamide, etoposide and high-dose cytarabine, and 23 (69.7%) patients were treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, high-dose methotrexate and high-dose cytarabine. The overall response rate for all patients was 78.8%, with a complete response rate of 72.7%. The two-year overall survival rate was 68.1%. There was no significant difference in overall survival between chemotherapeutic regimens with rituximab (n = 20) and without rituximab (n = 13) (P = 0.49). The two-year overall survival rate was 66.7% for patients receiving cyclophosphamide, vincristine, doxorubicin, dexamethasone, etoposide, ifosfamide and cytarabine, and was 72.6% for patients receiving cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate and cytarabine (P = 0.72). There was one treatment-related death.

CONCLUSIONS:

Highly intensive chemotherapy would bring a high remission rate and prolonged overall survival for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma.

• Authors: Yuki Kojima, Shotaro Hagiwara, Tomoko Uehira, Atsushi Ajisawa, Akira Kitanaka, Junko Tanuma, Seiji Okada, Hirokazu Nagai
• Journal: Japanese journal of clinical oncology (Jpn J Clin Oncol) Vol. 44 Issue 4 Pg. 318-23 (Apr 2014) ISSN: 1465-3621 [Electronic] England
• PMID: 24558129 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• Cytarabine
• Rituximab
• Vincristine
• Etoposide
• Dexamethasone
• Doxorubicin
• Cyclophosphamide
• Ifosfamide
• Prednisone
• Methotrexate

Topics

• Adult
• Aged
• Antibodies, Monoclonal, Murine-Derived (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
• Burkitt Lymphoma (drug therapy, mortality, pathology)
• Cyclophosphamide (administration & dosage)
• Cytarabine (administration & dosage)
• Dexamethasone (administration & dosage)
• Doxorubicin (administration & dosage)
• Drug Administration Schedule
• Etoposide (administration & dosage)
• Female
• Humans
• Ifosfamide (administration & dosage)
• Induction Chemotherapy
• Japan (epidemiology)
• Kaplan-Meier Estimate
• Lymphoma, AIDS-Related (drug therapy, mortality, pathology)
• Male
• Methotrexate (administration & dosage)
• Middle Aged
• Prednisone (administration & dosage)
• Retrospective Studies
• Rituximab
• Treatment Outcome
• Vincristine (administration & dosage)